JavaScript is disabled. Please enable to continue!
Mobile search icon
Bioanalysis >> About Us >> Latest News

Latest News

Sidebar Image

December 2018

October 2018

September 2018

June 2018

April 2018

January 2018

August 2017

October 2016

April 2015

February 2015

January 2015


Vimal Patel joins Eurofins Bioanalytical Services as Scientific Director for Large
Molecule Bioanalysis

St Charles, December 2015


Eurofins Bioanalytical Services is part of the broad-service Eurofins Pharma Services Group and a leading provider of bioanalytical testing to the biopharmaceutical today announced that Vimal Patel has joined the company as Scientific Director for large molecule bioanalysis based at the company's St Charles, MO facility.

Click here to read the full story

Eurofins Bioanalytical Services introduces GLP-compliant Singulex® Erenna® services

St Charles, April 2015

Eurofins Bioanalytical Services, a leading provider of bioanalytical testing to the biopharmaceutical industry, today announced introduction of services on the Singulex Erenna Immunoassay platform. The system is the latest high-tech addition to the laboratory that focuses on the Bioanalysis of large molecule therapeutics.

Biopharmaceutical companies face ever more demanding technical challenges in their quest to develop safer, better drugs. The Singulex Erenna immunoassay system can detect proteins at the femtogram / mL level, enabling the measurement of ultra-low levels of protein. The platform is used in pharmacokinetic studies, to measure biomarkers, and evaluate the immune response to administered large molecule therapeutics- especially where detection levels are a challenge.

"The Erenna immunoassay system, powered by Singulex's SMC™ technology, provides unprecedented quantification of protein targets at low and high abundance, providing a complete data set for a sponsor to make informed decisions and accelerate program success," said Dr. Paul Wheeler, Vice President of Life Science Sales and Marketing at Singulex. "Eurofins Bioanalytical Services is a trusted outsourcing partner for many in the pharma industry, and we are pleased that they have added the Erenna system to their Bioanalytical Lab Services offering."

Eurofins has already partnered with several of our clients to develop and transfer novel methods on the Erenna system. " said Dr Jim Hulse, General Manager of Eurofins Bioanalytical Services, " we look forward to working with additional users of the platform as we begin offering services using the existing biomarker assay kits available from Singulex"

For enquiries please contact us. 


David Lanham to present on Innovations in Flow Cytometry at the 10th Annual Biomarkers Congress

Oxford, February 2015

On 24th February. 9.00am - 9.30am during the Innovations in Biomarker Research track,  David Lanham, Scientific Director at Eurofins Bioanalytical Services will present:  Innovation Through Regulation: How The Recent FDA Biomarker Guidance Is Driving Changes In The Approach To Regulated Flow Cytometry Studies

Click here to read the full story 


New Bioanalytical Laboratory in Oxford, UK.

Oxford, January 2015

On January 8th  Eurofins Pharma Bioanalysis Services UK moved to its new 900m2 facility in Milton Park, Oxford UK. The new state-of-the-art laboratory will be the Eurofins Group hub for large molecule bioanalytical services in Europe, with significantly increased capacity and greater efficiency.

Click here to read the full story 


Pre-qualified assays to biosimilar trastuzumab

St Charles and Oxford, November 2014

Evaluation of the comparability of trastuzumab biosimilars to the innovator drug should follow the guidelines laid out by the FDA and EMA. The analysis should be multifactorial, taking into account both the physicochemical characteristics and clinical performance of the biosimilar compared to the innovator.

Eurofins Bioanalytical Services has launched a full range of off-the-shelf trastuzumab assays for comparability testing of biosimilars including PK, ADA & Nab, FcR and C1q binding and Her2 binding.

Click here for more details.